Company Overview November 4, 2025 1 Disclaimers This presentation contains forward-looking statements. All statements contained in this presentation other than statements of historical facts, including, without limitation, statements regarding our market opportunity, demand for our product and service offerings, expectations regarding our annualized recurring revenue (ARR), free cash flow, and our other non-GAAP measures, our business strategy, plans and objectives for future operations and expectations reg ...

Stoke Therapeutics Third Quarter 2025 Business Update Webcast for Investors & Analysts November 4, 2025 © COPYRIGHT 2025 | STOKE THERAPEUTICS | 1 Forward-Looking Statements and Other Legal Notices This presentation has been prepared by Stoke Therapeutics, Inc. ("Stoke" or "us") for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter(s) or Stoke or any officer, director, e ...

Financial Performance - Q3 2025 revenue increased by 84.7% year-over-year to $334.2 million, compared to $180.9 million in Q3 2024[47] - Genomics revenue totaled $252.9 million in Q3 2025, a 117.2% increase compared to Q3 2024[51] - Data and Services revenue reached $81.3 million in Q3 2025, a 26.1% increase compared to Q3 2024[51] - Gross profit improved by 98.4% year-over-year, reaching $209.9 million in Q3 2025, compared to $105.8 million in Q3 2024[47] - Adjusted EBITDA was $1.5 million in Q3 2025, a $23.3 million improvement from $(21.8) million in Q3 2024[47] Genomics Business - Oncology testing (Tempus Genomics) revenue was $139.5 million in Q3 2025, a 31.7% year-over-year increase[51] - Hereditary testing (Ambry Genetics) revenue was $102.6 million in Q3 2025, a 32.8% increase on a pro forma basis[51] - Hereditary tests delivered in Q3 2025 were approximately 129,500, with an average reimbursement per test of $790[24] Data and Services - Total Remaining Contract Value (TCV) for Data and Services was over $940 million at the end of 2024[34] - Data Licensing Retention was approximately 140% at the end of 2024[34] Guidance - Full year 2025 revenue guidance increased to approximately $1.265 billion, representing approximately 80% annual growth[60]

3Q Earnings Presentation November 2025 Copyright © 2025 agilon health. Confidential internal document containing proprietary information. Do not distribute. Disclaimers and Forward-Looking Statements FORWARD-LOOKING STATEMENTS AND OTHER INFORMATION Statements in this presentation that are not historical factual statements are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-lo ...

Financial Performance - Q3'25 - Public Cloud ARR reached $633 million, an increase of 11% year-over-year (YoY) and comprises 42% of Total ARR[9, 15] - Total ARR was $1490 billion, up 1% YoY[9] - Recurring revenue was $366 million, a decrease of 2% YoY[13] - Total revenue was $416 million, a decrease of 5% YoY[13, 21] - GAAP Diluted EPS was $042, an increase from $033 in Q3'24[13] - Non-GAAP Diluted EPS was $072, an increase from $069 in Q3'24[13] - Cash Flow from Operations was $94 million, an increase from $77 million in Q3'24[13] - Free Cash Flow was $88 million, an increase from $69 million in Q3'24[13] Financial Outlook - FY25 - Public cloud ARR is expected to grow 14% to 18% YoY in constant currency[43] - Total ARR is expected to grow flat to 2% YoY in constant currency[43] - Free cash flow is projected to be in the range of $260 million to $280 million[45]

Financial Performance - Net product revenue reached $38.5 million in Q3 2025[11], a 15% or $4.9 million increase compared to Q2 2025[11, 17] - The company is raising its 2025 net product revenue guidance to $145 million - $150 million[11, 29] - Year-to-date net product revenue for 2025 reached $102.6 million, exceeding the full-year 2024 revenue by approximately 89%[19] - The company has a strong financial position with $452 million in cash[11] OJEMDA Launch Performance - There was an 18% growth in total prescriptions, with 1,256 prescriptions (TRx) in Q3 2025[15] - New patient starts increased by 19%[15, 21] - Adoption of OJEMDA in the 2L setting grew by over 60% in the past 12 months[23] Pipeline Progress - Tovorafenib EMA regulatory decision is expected in 2026[11] - FIREFLY-2 trial enrollment completion is expected in the first half of 2026[11] - Three-year follow-up data from FIREFLY-1 will be presented at the SNO conference[11, 30]

Market Opportunity - MNTN's near-term market opportunity is approaching $120 billion[9, 11] - The U S performance advertising market is estimated at $285 billion with a '25-'27 CAGR of 9 7%[15] - The total U S advertising market is $399 billion with a '25-'27 CAGR of 6 8%[13] - The U S TV advertising market is $84 billion with a '25-'27 CAGR of 1 1%[17] Customer Acquisition and Performance - 97% of MNTN's customers never advertised on TV before[22, 23] - MNTN saw a 67% increase in active PTV customers[24] - Build with Ferguson generated $3 6 billion in advertiser revenue through MNTN campaigns[148, 150] - ThirdLove generated $12 2 million in advertiser revenue with MNTN, averaging a 7 85x ROAS from January 2023 to December 2024[156, 161] - Tarte generated $33 1 million in advertiser revenue with MNTN, with 13% of Tarte's total revenue being generated by MNTN[164] - woom generated $7 9 million in advertiser revenue with MNTN, representing 19% of woom's total U S DTC revenue from March 2023 to the end of 2024[171, 172] Financial Highlights - MNTN's revenue in 2024 was $226 million[99] - MNTN's adjusted EBITDA in 2024 was $39 million[101] - MNTN's client generated revenue from 2020 to 2024 was $25 2 billion[100] - Q3 2025 total revenue was $70 million, with a gross margin of 78 9%[106] - Q3 2025 adjusted EBITDA was $16 million, representing an adjusted EBITDA margin of approximately 23%[106]

Financial Performance - Q3 2025 revenue increased by 11.9% year-over-year[12] - Year-to-date revenue is up 12.1%[12] - Non-GAAP gross margins reached 80.7% in Q3 2025[12] - GAAP EPS stands at $0.17, while Non-GAAP EPS is $0.23[12] - Adjusted EBITDA for Q3 2025 is $21.9 million[18] Revenue Breakdown - Service Provider revenue year-to-date is $128.4 million[22] - Enterprise revenue year-to-date is $81.8 million[22] - Americas accounted for 65% of Q3 2025 revenue, totaling $74.7 million[25] Balance Sheet - The company holds $86.6 million in cash and cash equivalents as of September 30, 2025[37] - Marketable securities amounted to $284.3 million[37] - Long-term debt stands at $218.5 million[37]

MasterBrand Overview - MasterBrand is the 1 North American residential cabinet manufacturer with $2.7 billion in 2024 net sales[6,7] - Approximately 60% of net sales are attributed to R&R (Repair and Remodel)[7] - The company has a dealer network of over 7,700 and employs over 13,000 people across 20+ manufacturing facilities[7] - The company's 2024 Adjusted EBITDA was $364 million[7] Q3 2025 Financial Performance - Net sales for Q3 2025 were $698.9 million, a decrease of 2.7% compared to $718.1 million in Q3 2024[30] - Gross profit decreased by 8.3% from $238.0 million in Q3 2024 to $218.2 million in Q3 2025[30] - Net income decreased by 37.8% from $29.1 million in Q3 2024 to $18.1 million in Q3 2025[30] - Adjusted EBITDA decreased by 13.3% from $104.5 million in Q3 2024 to $90.6 million in Q3 2025[30] - Diluted EPS (GAAP) decreased by 36.4% from $0.22 in Q3 2024 to $0.14 in Q3 2025[30] - Free cash flow (YTD) decreased by 54.3% from $142.3 million in 2024 to $65.0 million in 2025[30] Full Year 2025 Outlook - The company anticipates a high to mid-single-digit percentage decline in the North American cabinets market[31] - The company expects net sales to be approximately flat[31] - The company projects adjusted EBITDA to be between $315 million and $335 million, with an adjusted EBITDA margin of approximately 11.5%-12.0%[31] - The company forecasts adjusted diluted EPS to be between $1.01 and $1.13[31] Long-Term Financial Targets - The company aims for a 3-5% CAGR in the North American Cabinets Market[36] - The company targets a 4-6% CAGR in Net Sales[36] - The company aims for an adjusted EBITDA margin of approximately 16%-18%[36] Additional Information - Strategic transformation initiatives have created >$180 million of cumulative annual savings since 2019, with another $50 million of incremental savings anticipated in 2025[27] - The company expects annual run-rate cost synergies of $90 million by the end of year three, following the close of the American Woodmark merger[29]

Q3 2025 Financial Results Presentation November 4, 2025 1 Forward Looking Statements Raul Rodriguez President & Chief Executive Officer Ray Furey, J.D. Executive Vice President, General Counsel & Corporate Secretary This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA") relating to, among other things, continued development and expansion of our business, projected financial performance including sales and revenue growth, con ...